Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study-Reference-Cited by-同舟云学术

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study

Published:2016-12 Issue:12 Volume:17 Page:1643-1652
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Goss Glenwood,Tsai Chun-Ming,Shepherd Frances A,Bazhenova Lyudmila,Lee Jong Seok,Chang Gee-Chen,Crino Lucio,Satouchi Miyako,Chu Quincy,Hida Toyoaki,Han Ji-Youn,Juan Oscar,Dunphy Frank,Nishio Makoto,Kang Jin-Hyoung,Majem Margarita,Mann Helen,Cantarini Mireille,Ghiorghiu Serban,Mitsudomi Tetsuya

Publisher

Elsevier BV

Subject

Oncology

Reference29 articles.

1. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Reck;Ann Oncol,2014

2. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy;Keedy;J Clin Oncol,2011

3. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

4. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol,2012

5. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations;Sequist;J Clin Oncol,2013

Cited by 555 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evidence Following Conditional NICE Technology Appraisal Recommendations: A Critical Analysis of Methods, Quality and Risk of Bias;PharmacoEconomics;2024-09-09

2. Using non-randomized trials to assess the clinical benefit of systemic anti-cancer treatments: Viable or not?;European Journal of Cancer;2024-09

3. Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial;Lung Cancer;2024-09

4. Exposure–response modelling of osimertinib in patients with non‐small cell lung cancer;British Journal of Clinical Pharmacology;2024-08-19

5. Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation–Positive Non–Small Cell Lung Cancer (BLOSSOM);Journal of Clinical Oncology;2024-08-10